Suchergebnisse - "Hardt, Karin"

PubPharm (7)

1

Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2) : results of a randomised, double-blind, placebo-controlled, phase 3 trial

enthalten in: The Lancet. Infectious diseases | 2022

von Hardt, K. | Vandebosch, A. | Sadoff, J. | +115

CommentIn: Lancet Infect Dis. 2022 Dec;22(12):1654-1655. - PMID 36113536

2

Vaccine strategies : Optimising outcomes

enthalten in: Vaccine | 2016

von Hardt, K. | Bonanni, P. | King, S. | +4

3

Primary and booster vaccination with an inactivated poliovirus vaccine (IPV) is immunogenic and well-tolerated in infants and toddlers in China

enthalten in: Vaccine | 2016

von Li, R. | Li, C. | Li, Y. | +8

4

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 7-year follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

enthalten in: The lancet / Infectious diseases | 2016

von Wheeler, C. | Skinner, S. | Del Rosario-Raymundo, M. | +33

5

Vaccine strategies: Optimising outcomes

enthalten in: Vaccine | 2016

von Hardt, K. | Bonanni, P. | King, S. | +4

6

Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age

enthalten in: Vaccine | 2015

von Avdicova, M. | Crasta, P. | Hardt, K. | +1

7

Immunogenicity and reactogenicity of a decennial booster dose of a combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and inactivated poliovirus booster vaccine (dTpa-IPV) in healthy adults

enthalten in: Vaccine | 2015

von Rathi, N. | Hardt, K. | Schwarz, T. | +2

1
[1]